A license that the Department of Defense plans to issue to Sanofi Pasteur for a Zika virus vaccine is being questioned by an advocacy group over concerns the product may be priced too high for many Americans, even though it was developed with taxpayer funds. And the issue is being raised as vaccine makers chase what some believe may become a lucrative market.

Here’s the backstory: On Dec. 9, the Army placed a brief notice in the Federal Register indicating its intent to give an exclusive license to Sanofi Pasteur, one of the world’s biggest vaccine makers and a unit of the French pharmaceutical company. The move followed months of mounting alarm among public health officials over the spread of Zika, the mosquito-borne virus that can cause birth defects.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • It is also standard practice that licensing agreements in pharma are treated as proprietary and trade secret information with respect to the specifics of the income streams from the royalty bearing license. For all we know a decent percentage of the royalties will go back to the US Treasury, effectively reimbursing taxpayers.

    Anyone wanting more details is free to file a FOIA request, but since the military and pharma are two of the most secretive entities in the world don’t expect to get too far with that.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy